Regulation of Necroptosis and inflammation

坏死性凋亡和炎症的调节

基本信息

  • 批准号:
    10534748
  • 负责人:
  • 金额:
    $ 35.64万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-01-01 至 2023-12-31
  • 项目状态:
    已结题

项目摘要

Abstract The term programmed necrosis or necroptosis has been used to distinguish several types of cell death such as apoptosis, autophagy, and pyroptosis. Necroptosis has been linked to inflammation response and diseases, which is a contributing factor for tumor initiation and progression. The protein kinase RIP1 and RIP3 are critical for the activation of necroptosis. Many studies have shown a complex functional interplay between RIP1 and RIP3 in regulating necrosome formation and necroptosis. Misregulation of this pathway would trigger abnormal tissue homeostasis, inflammation response, and caner initiation or progression. For example, abnormal RIP3-induced necroptosis in intestinal epithelium cause inflammatory bowel disease, which is linked to the development of colorectal cancer. Although RIP3 is a crucial kinase in necroptosis, how RIP3 is regulated in cells is not clear. We recently found that Parkin regulates RIP3 during necroptosis. Parkin is an E3 ubiquitin ligase that is encoded by the PARK2 gene. Mutation in the PARK2 gene is the most frequent cause of autosomal recessive early onset of Parkinson's Disease (PD). Emerging evidence suggests that Parkin also functions as a tumor suppressor, although how Parkin functions as a tumor suppressor remains unclear. Recently, we found that Parkin is a negative regulator of necroptosis and inflammation. Parkin promotes RIP3 ubiquitination, inhibits RIP3 phosphorylation, necrosome formation, and necroptosis in various cells. Conversely, deletion of the Parkin gene results in increased necroptosis. Importantly, deletion of the Park2 gene promotes inflammation and hyperplasia in vivo. Interestingly, we also found that Parkin itself is regulated by AMP-activated protein kinase (AMPK). Based on these preliminary results, we hypothesize that the AMPK-Parkin pathway is an important negative regulator of RIP3 by promoting RIP3 ubiquitination and inactivation. Further, the AMPK-Parkin-RIP3 pathway suppresses inflammation-induced tumorigenesis. To test this hypothesis, we propose the following Specific Aims: 1. To study the role of Parkin in RIP3 regulation and necroptosis; 2. To study the regulation of Parkin by AMPK; 3. To study the role of Parkin in inflammation and cancer. These studies will reveal a novel role of Parkin in the regulation of RIP3, necroptosis, and inflammation. In addition, a new mechanism by which Parkin functions as a tumor suppressor will be revealed. Accordingly, these studies will have a high impact for cancer pathogenesis and future cancer prevention. !
摘要 术语程序性坏死或坏死性凋亡已被用来区分几种类型的细胞死亡 如凋亡、自噬和焦亡。坏死性下垂与炎症反应有关, 疾病,这是肿瘤发生和发展的一个促成因素。蛋白激酶RIP 1和RIP 3 是激活坏死性凋亡的关键许多研究表明, RIP 1和RIP 3调节坏死体形成和坏死性凋亡。这条通路的失调会引发 异常的组织稳态、炎症反应和癌症的发生或发展。比如说, 异常RIP 3诱导的肠上皮坏死性凋亡导致炎症性肠病, 与结直肠癌的发展有关。虽然RIP 3是坏死性凋亡中的关键激酶,但RIP 3是如何在细胞凋亡中发挥作用的呢? 在细胞中的调控尚不清楚。我们最近发现帕金在坏死性凋亡过程中调节RIP 3。帕金是一个 由PARK 2基因编码的E3泛素连接酶。PARK 2基因突变是最常见的 常染色体隐性遗传帕金森病(PD)的早期发病的原因。新出现的证据表明 帕金也作为一种肿瘤抑制因子发挥作用,尽管帕金如何作为一种肿瘤抑制因子发挥作用仍然存在。 不清楚最近,我们发现Parkin是坏死性凋亡和炎症的负调节因子。帕金 促进RIP 3泛素化,抑制RIP 3磷酸化,坏死体形成和坏死性凋亡, 细胞相反,帕金基因的缺失导致坏死性凋亡增加。重要的是,删除 Park 2基因在体内促进炎症和增生。有趣的是,我们还发现帕金本身 由AMP激活的蛋白激酶(AMPK)调节。基于这些初步结果,我们假设, AMPK-Parkin通路通过促进RIP 3泛素化,是RIP 3的重要负调节因子 和失活。此外,AMPK-Parkin-RIP 3途径抑制炎症诱导的细胞凋亡。 肿瘤发生为了验证这一假设,我们提出了以下具体目标:1。研究帕金的角色 RIP 3调节和坏死性凋亡; 2.研究AMPK对Parkin的调节作用; 3.研究的作用 帕金在炎症和癌症。这些研究将揭示Parkin在RIP 3调节中的新作用, 坏死性凋亡和炎症。此外,帕金作为肿瘤发挥作用的一种新机制 抑制剂将被发现。因此,这些研究将对癌症发病机制产生很大影响, 未来的癌症预防 !

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Zhenkun Lou其他文献

Zhenkun Lou的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Zhenkun Lou', 18)}}的其他基金

ATR: targeting mechanical stress induced EMT and immune suppression in triple negative breast cancer
ATR:针对三阴性乳腺癌中机械应力诱导的 EMT 和免疫抑制
  • 批准号:
    10658429
  • 财政年份:
    2023
  • 资助金额:
    $ 35.64万
  • 项目类别:
Sensitizing Ovarian Cancer To PARP inhibitor and platinum treatment
卵巢癌对 PARP 抑制剂和铂类治疗敏感
  • 批准号:
    10305524
  • 财政年份:
    2021
  • 资助金额:
    $ 35.64万
  • 项目类别:
Sensitizing Ovarian Cancer To PARP inhibitor and platinum treatment
卵巢癌对 PARP 抑制剂和铂类治疗敏感
  • 批准号:
    10415197
  • 财政年份:
    2021
  • 资助金额:
    $ 35.64万
  • 项目类别:
Sensitizing Ovarian Cancer To PARP inhibitor and platinum treatment
卵巢癌对 PARP 抑制剂和铂类治疗敏感
  • 批准号:
    10610944
  • 财政年份:
    2021
  • 资助金额:
    $ 35.64万
  • 项目类别:
The role of nuclear PD-L1 in breast tumor cell division, progression and therapy response
核PD-L1在乳腺肿瘤细胞分裂、进展和治疗反应中的作用
  • 批准号:
    10553119
  • 财政年份:
    2020
  • 资助金额:
    $ 35.64万
  • 项目类别:
The role of nuclear PD-L1 in breast tumor cell division, progression and therapy response
核PD-L1在乳腺肿瘤细胞分裂、进展和治疗反应中的作用
  • 批准号:
    10361225
  • 财政年份:
    2020
  • 资助金额:
    $ 35.64万
  • 项目类别:
The role of nuclear PD-L1 in breast tumor cell division, progression and therapy response
核PD-L1在乳腺肿瘤细胞分裂、进展和治疗反应中的作用
  • 批准号:
    9897018
  • 财政年份:
    2020
  • 资助金额:
    $ 35.64万
  • 项目类别:
Regulation of Necroptosis and inflammation
坏死性凋亡和炎症的调节
  • 批准号:
    10316176
  • 财政年份:
    2019
  • 资助金额:
    $ 35.64万
  • 项目类别:
UFM1 signaling in DNA damage response and cancer therapy
DNA 损伤反应和癌症治疗中的 UFM1 信号传导
  • 批准号:
    10304188
  • 财政年份:
    2017
  • 资助金额:
    $ 35.64万
  • 项目类别:
UFM1 signaling in DNA damage response and cancer therapy
DNA 损伤反应和癌症治疗中的 UFM1 信号传导
  • 批准号:
    10057359
  • 财政年份:
    2017
  • 资助金额:
    $ 35.64万
  • 项目类别:

相似海外基金

Pharmacological targeting of AMP-activated protein kinase for immune cell regulation in Type 1 Diabetes
AMP 激活蛋白激酶对 1 型糖尿病免疫细胞调节的药理学靶向
  • 批准号:
    2867610
  • 财政年份:
    2023
  • 资助金额:
    $ 35.64万
  • 项目类别:
    Studentship
Establishing AMP-activated protein kinase as a regulator of adipose stem cell plasticity and function in health and disease
建立 AMP 激活蛋白激酶作为脂肪干细胞可塑性和健康和疾病功能的调节剂
  • 批准号:
    BB/W009633/1
  • 财政年份:
    2022
  • 资助金额:
    $ 35.64万
  • 项目类别:
    Fellowship
Determining the role of AMP-activated protein kinase in the integration of skeletal muscle metabolism and circadian biology
确定 AMP 激活蛋白激酶在骨骼肌代谢和昼夜节律生物学整合中的作用
  • 批准号:
    532989-2019
  • 财政年份:
    2021
  • 资助金额:
    $ 35.64万
  • 项目类别:
    Postdoctoral Fellowships
Metabolic control of integrin membrane traffic by AMP-activated protein kinase controls cell migration.
AMP 激活的蛋白激酶对整合素膜运输的代谢控制控制着细胞迁移。
  • 批准号:
    459043
  • 财政年份:
    2021
  • 资助金额:
    $ 35.64万
  • 项目类别:
    Studentship Programs
Determining the role of AMP-activated protein kinase in the integration of skeletal muscle metabolism and circadian biology
确定 AMP 激活蛋白激酶在骨骼肌代谢和昼夜节律生物学整合中的作用
  • 批准号:
    532989-2019
  • 财政年份:
    2020
  • 资助金额:
    $ 35.64万
  • 项目类别:
    Postdoctoral Fellowships
The Role of AMP-activated Protein Kinase in GVHD-causing T Cells
AMP 激活的蛋白激酶在引起 GVHD 的 T 细胞中的作用
  • 批准号:
    10561642
  • 财政年份:
    2019
  • 资助金额:
    $ 35.64万
  • 项目类别:
Determining the role of AMP-activated protein kinase in the integration of skeletal muscle metabolism and circadian biology
确定 AMP 激活蛋白激酶在骨骼肌代谢和昼夜节律生物学整合中的作用
  • 批准号:
    532989-2019
  • 财政年份:
    2019
  • 资助金额:
    $ 35.64万
  • 项目类别:
    Postdoctoral Fellowships
Treating Diabetic Inflammation using AMP-Activated Protein Kinase Activators
使用 AMP 激活的蛋白激酶激活剂治疗糖尿病炎症
  • 批准号:
    2243045
  • 财政年份:
    2019
  • 资助金额:
    $ 35.64万
  • 项目类别:
    Studentship
The Role of AMP-activated Protein Kinase in GVHD-causing T Cells
AMP 激活的蛋白激酶在引起 GVHD 的 T 细胞中的作用
  • 批准号:
    10359032
  • 财政年份:
    2019
  • 资助金额:
    $ 35.64万
  • 项目类别:
Investigating the therapeutic potential of AMP-activated protein kinase in myotonic dystrophy type 1
研究 AMP 激活蛋白激酶在 1 型强直性肌营养不良中的治疗潜力
  • 批准号:
    428988
  • 财政年份:
    2019
  • 资助金额:
    $ 35.64万
  • 项目类别:
    Studentship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了